TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1560163

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (400 mg tablet)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3157706

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 62
Study: 29754655

Group type: EXPERIMENTAL
Intervention: STEMI
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: UA/NSTEMI
Number of subjects: 83
Study: 26914263

Group type: EXPERIMENTAL
Intervention: Motives Feedback Condition (MFC)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard Feedback Condition (SFC)
Number of subjects: 170
Study: 24777019

Group type: EXPERIMENTAL
Intervention: Coronal muscle splitting technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no coronal muscle splitting)
Number of subjects: 24
Study: 22560357

Group type: EXPERIMENTAL
Intervention: Patient-centered tailored education and coaching (TEC)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Analgesic change (following TEC)
Number of subjects: 258
Study: 20923577

Group type: EXPERIMENTAL
Intervention: HSD/5D
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ringer's Lactate (RL)
Number of subjects: 61
Study: 18354285

Group type: EXPERIMENTAL
Intervention: FS 4IU VH S/D (fibrin sealant containing 4 IU/ml thrombin)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 138
Study: 17022376

Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment for 6 weeks
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment for 12 weeks
Number of subjects: 192
Study: 12749497

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 2178
Study: 10952474

Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg once daily in the morning
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg once daily in the evening
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8636663

Group type: EXPERIMENTAL
Intervention: Instructed group (given instruction on interchangeability)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Queried group (asked about basis for test-trial responding)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard group (neither instructed nor queried)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symmetry trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transitivity trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined transitivity and symmetry trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nodal distance (one through five nodes)
Number of subjects: 0
Study: 1627427

Group type: EXPERIMENTAL
Intervention: Breast conservation therapy
Number of subjects: 1153

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1153
Study: 6508324

Group type: EXPERIMENTAL
Intervention: Bestatin (B) with maintenance chemotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone (C)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Bestatin (B) in patients over 50 years of age
Number of subjects: 101

Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone (C) in patients over 50 years of age
Number of subjects: 101
Study: 31013182

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLN) 10 mg orally on days 1 to 4
Number of subjects: 64

Group type: COMPARATOR
Intervention: Haloperidol (HAL) 1 mg orally on day 1 and 0.5 mg twice daily on days 2 to 4
Number of subjects: 64
Study: 29494473

Group type: EXPERIMENTAL
Intervention: Tablet-based audiometric applications
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional audiometry
Number of subjects: 107
Study: 26537976

Group type: EXPERIMENTAL
Intervention: Preoperative depression (BDI score >3)
Number of subjects: 359

Group type: COMPARATOR
Intervention: No preoperative depression (BDI score ≤3)
Number of subjects: 359
Study: 25409545

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Resin infiltration
Number of subjects: 504

Group type: COMPARATOR
Intervention: Exclusively flossing (control group)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: SDF, Resin infiltration, Exclusively flossing
Number of subjects: 504
Study: 23019940

Group type: EXPERIMENTAL
Intervention: Compound Zhebei Granule (CZG)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (standard chemotherapy)
Number of subjects: 41
Study: 20596692

Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D(3)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin D(3)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 18047643

Group type: EXPERIMENTAL
Intervention: DECISION+ program in shared decision making (experimental group)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Delayed DECISION+ group (control group)
Number of subjects: 5
Study: 15661822

Group type: EXPERIMENTAL
Intervention: 3 months of training
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 6 months of training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Baseline (compared to controls)
Number of subjects: 22
Study: 12069174

Group type: EXPERIMENTAL
Intervention: 370 microg budesonide PulmoSphere inhaled from Eclipse DPI at target PIF of 25 L x min(‐1) (PSbud25)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 370 microg budesonide PulmoSphere inhaled from Eclipse DPI at target PIF of 50 L x min(‐1) (PSbud50)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 800 microg of pelletized budesonide from Pulmicort Turbuhaler at 60 L x min(‐1) (THbud60)
Number of subjects: 8
Study: 10417522

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment with diisopropyl adipate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment without diisopropyl adipate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.1% Betamethasone 17alpha-valerate ointment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.005% Calcipotriol ointment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vehicle controls for tacrolimus and betamethasone
Number of subjects: 16
Study: 7752328

Group type: EXPERIMENTAL
Intervention: Topical prostaglandin‐E1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2405783

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6994775

Group type: EXPERIMENTAL
Intervention: 3 mg orally
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2.3 mg intravenously
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Multiple dosing
Number of subjects: 14
Study: 30341026

Group type: EXPERIMENTAL
Intervention: EyeBag (10 minutes, 2x/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (own dry eye treatment regimen)
Number of subjects: 29
Study: 28386990

Group type: EXPERIMENTAL
Intervention: iGlarLixi (insulin glargine 100 U plus lixisenatide)
Number of subjects: 736
Study: 25575084

Group type: EXPERIMENTAL
Intervention: Minimally invasive decompression (MID)
Number of subjects: 96

Group type: COMPARATOR
Intervention: X-Stop
Number of subjects: 96
Study: 23644132

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 µg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study: 22107875

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 36
Study: 19252348

Group type: EXPERIMENTAL
Intervention: L-thyroxin treatment before and after
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (euthyroid healthy volunteers)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of patient group to control group
Number of subjects: 30
Study: 17255299

Group type: EXPERIMENTAL
Intervention: High-dose bolus interleukin 2 (IL-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower doses of IL-2 (either alone or in combination with IFN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose IL-2 therapy
Number of subjects: 0
Study: 15208972

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual treatment (comparison group)
Number of subjects: 70
Study: 11476927

Group type: COMPARATOR
Intervention: Short aortic cannula (aorta ascendens)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Elongated aortic cannula (aorta descendens)
Number of subjects: 60
Study: 9713297

Group type: COMPARATOR
Intervention: Epidoxorubicin (100 mg/m2) and Cyclophosphamide (600 mg/m2) on day 1 (group A)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Epidoxorubicin and Cyclophosphamide plus GM-CSF (5 micrograms/kg/day) from days 3 to 12 (group B)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Epidoxorubicin and Cyclophosphamide plus GM-CSF from days -6 to -3 (group C)
Number of subjects: 73
Study: 8274110

Group type: EXPERIMENTAL
Intervention: High-volume contrast computed tomographic scan of the brain plus trimodal evoked potentials
Number of subjects: 204

Group type: COMPARATOR
Intervention: Magnetic resonance imaging of the brain
Number of subjects: 204
Study: 2731771

Group type: EXPERIMENTAL
Intervention: Silver cannula
Number of subjects: 168

Group type: COMPARATOR
Intervention: Portex catheter
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Combined group (after failure of initial device)
Number of subjects: 168
Study: 4713987

Group type: EXPERIMENTAL
Intervention: Hexachlorophane disinfection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain soap
Number of subjects: 0
Study: 31411376

Group type: EXPERIMENTAL
Intervention: High acceptability (HA) custard
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low acceptability (LA) custard
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Participants with obesity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Participants with normal weight
Number of subjects: 30
Study: 27480340

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 25218539

Group type: EXPERIMENTAL
Intervention: Prophylactic peritoneal dialysis catheter (PDC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care (no PDC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prophylactic PDC
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 22
Study: 23258640

Group type: EXPERIMENTAL
Intervention: Vitamin E + verapamil (injection + iontophoresis) + blueberries + propolis + topical diclofenac
Number of subjects: 70

Group type: COMPARATOR
Intervention: Verapamil (injection + iontophoresis) + blueberries + propolis + topical diclofenac
Number of subjects: 70
Study: 21275979

Group type: EXPERIMENTAL
Intervention: Intranasal lorazepam (0.1 mg/kg, maximum 4 mg)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Intravenous lorazepam (0.1 mg/kg, maximum 4 mg)
Number of subjects: 141
Study: 19074920

Group type: EXPERIMENTAL
Intervention: MRI biometry
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: A-scan echography
Number of subjects: 70
Study: 16401473

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 178

Group type: COMPARATOR
Intervention: Gallbladders left in situ
Number of subjects: 178
Study: 15510707

Group type: COMPARATOR
Intervention: NPSV at patient's comfort (C)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: NPSV at physiological setting (PH)
Number of subjects: 23
Study: 11794169

Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy
Number of subjects: 263

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 263
Study: 9442424

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (Total, Colgate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supragingival plaque control
Number of subjects: 40
Study: 7954041

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg od, increased to 8 mg od if DBP > 90 mmHg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Diltiazem (120 mg [60 mg bid], increased to 360 mg [180 mg bid] if DBP > 90 mmHg)
Number of subjects: 49
Study: 3312113

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg OD
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nadolol 160 mg OD
Number of subjects: 98

Group type: COMPARATOR
Intervention: Propranolol 160 mg bid
Number of subjects: 98
Study: 30009968

Group type: EXPERIMENTAL
Intervention: Fan therapy directed to the patient's face for five minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fan therapy directed to the patient's legs (control group)
Number of subjects: 40
Study: 27506635

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of ezetimibe 10 mg plus rosuvastatin (5, 10, or 20 mg daily)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Rosuvastatin alone (5, 10, or 20 mg daily)
Number of subjects: 407
Study: 24664228

Group type: EXPERIMENTAL
Intervention: Ilizarov circular fixator (IL)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Locked intramedullary nailing (IM)
Number of subjects: 58
Study: 22342928

Group type: EXPERIMENTAL
Intervention: Gel-200
Number of subjects: 379

Group type: COMPARATOR
Intervention: PBS (control)
Number of subjects: 379
Study: 20213795

Group type: EXPERIMENTAL
Intervention: HELP-apheresis plus standard treatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 132
Study: 18725832

Group type: EXPERIMENTAL
Intervention: Computer-based educational program on colorectal cancer screening
Number of subjects: 199
Study: 15932816

Group type: EXPERIMENTAL
Intervention: Sertraline (N=23)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (N=32)
Number of subjects: 55
Study: 11909901

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional antipsychotic drugs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Switching from conventional to risperidone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Switching from risperidone to conventional
Number of subjects: 12
Study: 11464953

Group type: EXPERIMENTAL
Intervention: r‐metHuBDNF (25, 60, 150, 400 or 1000 microg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: r‐metHuBDNF (doses >150 microg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: r‐metHuBDNF
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: r‐metHuBDNF (up to 150 microg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10179580

Group type: EXPERIMENTAL
Intervention: Evolutionary artificial neural networks (EANN)
Number of subjects: 0
Study: 8443479

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Porcine insulin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison of both insulins
Number of subjects: 17
Study: 3533566

Group type: EXPERIMENTAL
Intervention: 5 mg dihydroergotamine (DHE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg dihydroergotamine (DHE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29408561

Group type: EXPERIMENTAL
Intervention: High-dose supplemental vitamin D3 (2000 IU/day)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1 g/day)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 771
Study: 29071929

Group type: EXPERIMENTAL
Intervention: Mild moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60
Study: 25479227

Group type: EXPERIMENTAL
Intervention: 940nm diode laser treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bipolar radiofrequency therapy
Number of subjects: 27
Study: 24669646

Group type: EXPERIMENTAL
Intervention: Oral clonidine 0.2 mg + I/V fentanyl 2 microg/Kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral placebo + I/V fentanyl 2 microg/Kg
Number of subjects: 60
Study: 20739418

Group type: EXPERIMENTAL
Intervention: High-SFA and HGI diet (HS/HGI)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: High-MUFA and HGI diet (HM/HGI)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: HM and LGI diet (HM/LGI)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Low-fat and HGI diet (LF/HGI)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Low-fat and LGI diet (LF/LGI)
Number of subjects: 548

Group type: COMPARATOR
Intervention: SFA reduction
Number of subjects: 548

Group type: COMPARATOR
Intervention: Fat reduction
Number of subjects: 548
Study: 18294508

Group type: EXPERIMENTAL
Intervention: secretin-stimulated ePFT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dreiling PFT
Number of subjects: 24
Study: 16188207

Group type: EXPERIMENTAL
Intervention: Flax oil (60 g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish oil (60 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Olive oil (< 1% omega‐3 fatty acids)
Number of subjects: 30
Study: 12816171

Group type: EXPERIMENTAL
Intervention: High-dose lisinopril (32.5-35.0 mg/day)
Number of subjects: 3164
Study: 10816235

Group type: EXPERIMENTAL
Intervention: Cryotherapy with liquid nitrogen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Localized dermabrasion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 10
Study: 8788540

Group type: EXPERIMENTAL
Intervention: Mental arithmetic with harassment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cold pressor task
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both stressor groups
Number of subjects: 31
Study: 31421664

Group type: EXPERIMENTAL
Intervention: Shallot (3g per day) and cetirizine (10 mg once daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cetirizine (10 mg once daily) and placebo capsules
Number of subjects: 16
Study: 29891614

Group type: EXPERIMENTAL
Intervention: Adductor Strengthening Programme (Copenhagen Adduction exercise), performed three times per week during preseason (6-8 weeks) and once per week during competitive season (28 weeks)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Control group (normal training)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Adductor Strengthening Programme
Number of subjects: 652
Study: 29183775

Group type: EXPERIMENTAL
Intervention: Isoflavone pills (60 mg genistein, 60 mg daidzein, 16.6 mg glycitein)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 197
Study: 27849214

Group type: EXPERIMENTAL
Intervention: Colgate Slim Soft toothbrush
Number of subjects: 70

Group type: COMPARATOR
Intervention: Curaprox CS5460 toothbrush
Number of subjects: 70
Study: 23412304

Group type: EXPERIMENTAL
Intervention: Robot-assisted rehabilitation training
Number of subjects: 60
Study: 23216922

Group type: EXPERIMENTAL
Intervention: Feedback + Advice group (FA) - personal genetic test result for FTO gene + leaflet with weight control advice
Number of subjects: 800

Group type: COMPARATOR
Intervention: Advice Only group (AO) - leaflet with simple weight control advice
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Both groups (FA and AO)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Feedback + Advice group (FA)
Number of subjects: 800
Study: 18245967

Group type: EXPERIMENTAL
Intervention: loteprednol etabonate/tobramycin
Number of subjects: 306

Group type: COMPARATOR
Intervention: dexamethasone/tobramycin
Number of subjects: 306
Study: 16547078

Group type: EXPERIMENTAL
Intervention: Ambient light reduction
Number of subjects: 188
Study: 14575666

Group type: EXPERIMENTAL
Intervention: Bilateral injection of hypertonic saline (two injections)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Unilateral injection of hypertonic saline (one injection)
Number of subjects: 2
Study: 10714088

Group type: EXPERIMENTAL
Intervention: Partial gastrectomy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 10
Study: 10202506

Group type: EXPERIMENTAL
Intervention: Povidone-iodine mouthwash
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8263311

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 136

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 136
Study: 3964515

Group type: EXPERIMENTAL
Intervention: Heat conservation during and after surgery (warming fresh gases, i.v. fluids, warmed cotton padding, metallized plastic sheet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine management (control group)
Number of subjects: 0
Study: 30525844

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 26809813

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (10 mg/kg per day for 7 days)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Ceftriaxone (60 mg/kg up to 2 g per day for 7 days)
Number of subjects: 239
Study: 24698577

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS) - group A
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Locking DHS (Combi plate) - group B
Number of subjects: 50
Study: 23029966

Group type: EXPERIMENTAL
Intervention: Yoga training group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 20380778

Group type: EXPERIMENTAL
Intervention: Verbal Repetition (VR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 0
Study: 18385577

Group type: EXPERIMENTAL
Intervention: Transparent absorbent acrylic dressing (TAAD)
Number of subjects: 72
Study: 16612101

Group type: EXPERIMENTAL
Intervention: Thermal Balloon Endometrial Ablation (TBEA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Levonorgestrel Intrauterine System (LNG-IUS)
Number of subjects: 44
Study: 12941712

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin intervention
Number of subjects: 0
Study: 11072284

Group type: EXPERIMENTAL
Intervention: Outpatient nursing case management for cardiovascular disease
Number of subjects: 0